“It’s $1 trillion in cuts over a decade and $50 billion to help try to shore it up,” Rob Davidson, an emergency physician in ...

One reason why many investors could be asking this question is Pfizer's high dividend payout ratio of 99.4%. This metric ...

By the beginning of 2025, it was clear the GLP-1 drugs were going to remain a major part of the industry. Pfizer used its presentation at the 43 rd JP Morgan Healthcre Conference to detail plans to ...

Founder of the Genesis Prize Stan Polovets on why your seventies and eighties – and even nineties – can be your most ...

Stories on the efficacy of science-based treatments and consumers' thirst for knowledge were topics in most-read health stories.

If pharmaceutical drug patents are an hourglass turned over on the day of approval - with the approaching loss of exclusivity known in the industry as the "patent cliff" - then Big Pharma is currently ...

We recently published 12 Stocks on Jim Cramer’s Radar. Pfizer Inc. (NYSE:PFE) is one of the stocks on Jim Cramer’s radar. Pfizer Inc. (NYSE:PFE)’s shares are down by 5.90% year-to-date, and December ...

The pharmaceutical company updated its sales guidance for 2025, saying it now expects $62 billion in revenue for the year.

Pfizer (PFE) CEO Albert Bourla said he's learned to work with some unlikely allies — even those who once questioned the very foundation of his business. "Clearly, that was not going to be my choice ...

Pfizer Chief Executive Albert Bourla had long searched for an obesity drug to make up for dwindling sales of the pharma company’s aging blockbusters. Late Friday, after a dramatic bidding war, he ...